Cordero-Pérez Paula, Hernández-Cruz Flor Edith, Garza-Guzmán Daniel, Moreno-Peña Diana Patricia, Sánchez-Martínez Concepción, Torres-González Liliana, Muñoz-Espinosa Linda E, Zapata-Chavira Homero, Cura-Esquivel Idalia, Serrano-Sandoval Marisol Idalí, Rodríguez-Rodríguez Diana Raquel
Liver Unit, Department of Internal Medicine, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, Mexico.
Nephrology Service, Department of Internal Medicine, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, Mexico.
Pharmaceuticals (Basel). 2024 Aug 29;17(9):1135. doi: 10.3390/ph17091135.
Diabetes mellitus presents a great diversity of treatments that cause adverse effects; therefore, plants are a source of compounds that may have fewer adverse effects; () has compounds with potential antidiabetic activity. The objective was to evaluate the antidiabetic effect of oil (CCO) and its impact on oxidative stress in Wistar rats. Five groups were evaluated: (1) sham (SH), (2) 300 mg/kg CCO (CCO), (3) diabetic (D) induced with alloxan, (4) D + 300 mg/kg of CCO (D + CCO), and (5) D + 500 mg/kg of metformin (D + MET); all were treated for 5 days. CCO did not show alteration in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) vs. SH. D + CCO vs. D significantly reduced glucose (333 ± 109 vs. 458 ± 81 mg/dL), ALT (66 ± 15 vs. 160 ± 54 U/L), AST (119 ± 26 vs. 243 ± 104 U/L), and blood urea nitrogen (18.8 ± 2.3 vs. 29.2 ± 6.9 mg/dL). No significant changes were observed in D + CCO vs. D in malondialdehyde (MDA), reduced glutathione (GSH), and superoxide dismutase (SOD), whereas a significant reduction in MDA and GSH was achieved in D + MET, with an increase in SOD. There was a reduction in and in D + CCO and D + MET vs. D. CCO has antidiabetic and anti-inflammatory effects and reduces ALT, AST, and BUN levels.
糖尿病有各种各样会引发不良反应的治疗方法；因此，植物是可能具有较少不良反应的化合物的来源；（）含有具有潜在抗糖尿病活性的化合物。目的是评估（某植物）油（CCO）对Wistar大鼠的抗糖尿病作用及其对氧化应激的影响。评估了五组：（1）假手术组（SH），（2）300毫克/千克CCO组（CCO），（3）用四氧嘧啶诱导的糖尿病组（D），（4）糖尿病 + 300毫克/千克CCO组（D + CCO），以及（5）糖尿病 + 500毫克/千克二甲双胍组（D + MET）；所有组均治疗5天。与SH组相比，CCO组的天冬氨酸转氨酶（AST）和丙氨酸转氨酶（ALT）未显示出变化。与D组相比，D + CCO组显著降低了血糖（333±109对458±81毫克/分升）、ALT（66±15对160±54 U/L）、AST（119±26对243±104 U/L）和血尿素氮（18.8±2.3对29.2±6.9毫克/分升）。与D组相比，D + CCO组在丙二醛（MDA）、还原型谷胱甘肽（GSH）和超氧化物歧化酶（SOD）方面未观察到显著变化，而D + MET组MDA和GSH显著降低，SOD升高。与D组相比，D + CCO组和D + MET组的（某些指标）有所降低。CCO具有抗糖尿病和抗炎作用，并降低ALT、AST和BUN水平。
